Destination Country
Global
Key objectives

Rapidly develop candidate vaccine/s against SARS-CoV-2 through Preclinical and clinical development in 12-18 month timeframe with aim of achieving EUAL/ licensure for equitable use in epidemic settings, to ensure the availability of sufficient doses for wide-spread global deployment as soon as possible in 2021.

Contribution Area
IHR Coordination, Communication and Advocacy
Biosafety and Biosecurity
Immunization
Surveillance
Emergency Preparedness
Linking Public Health and Security Authorities
Medical Countermeasures and Personnel Deployment
Flexible Support
Source Entity
Coalition for Epidemics Preparedness Innovations (CEPI)
Type
Financial
In Kind
Status
Ongoing
Activity
9 vaccine candidates selected and currently being funded from Preclinical and Clinical stages. See updates on https://cepi.net/research_dev/our-portfolio/
Year (From)
01-01-2020
Contribution channel
Partner
Coverage
Worldwide
PHE Category
Epidemics and Pandemics
Public Health Emergency
COVID-19